natgillin/translations-raw huggingface dataset:
A plasmid vector for DNA transfer, which plasmid contains a sequence consisting of SEQ ID N: 10 coding for a chimeric p 185neu protein. 
Vektorski plazmid za prijenos DNA, naznačen time da sadrži sekvenciju koja sadrži SEQ ID br: 10 koji kodira protein p185neu.
Pharmaceutical composition containing a plasmid vector according to claims 1-3 together with pharmaceutically acceptable vehicles and excipients. 
Farmaceutski pripravak koji sadrži vektorski plazmid prema patentnim zahtjevima 1-3, naznačen time da je skupa s farmaceutski prihvatljivim vezikulima i ekscipijensima.
Composition according to claim 6 in the form of an injectable solution. 
Pripravak prema patentnom zahtjevu 6, naznačen time da je u obliku otopine za injekcije.
Use of a plasmid vector according to claims 1-4 for the preparation of a therapeutic agent to be used in the prevention or treatment of subjects at risk of developing p185neu-positive tumors, or patients carrying primary tumors, metastases or p 185neu-positive tumor relapses. 
Upotreba plazmidnog vektora prema patentnim zahtjevima 1-4, naznačena time da je za pripravu terapijskog sredstva za upotrebu u prevenciji ili tretmanu subjekata koji su rizični na razvoj p185neu-pozitivnih tumora, ili pacijenata koji nose primarne tumore, metastaze ili relaps p185neu-pozitivnog tumora.
A process for preparing an immunogenic composition for parenteral use in humans, comprising a step of preparing an oil-in-water emulsion by the process of any one of claims 1 to 17, and mixing the emulsion with an immunogen. 
Postupak za dobivanje cjepiva za parenteralnu upotrebu kod ljudi, naznačen time da sadrži korak dobivanja adjuvanta emulzija ulja u vodi pomoću postupka prema bilo kojem od zahtjeva 1 do 13, te miješanje emulzije adjuvanta sa imunogenom.
A process for preparing a kit for preparing an immunogenic composition, comprising preparing an oil-in-water emulsion for parenteral use in humans by the process of any one of claims 1 to 17, packaging the emulsion in a first container, and combining the first container in kit form with a second container, wherein the second container contains an immunogen. 
Postupak za dobivanje kita za dobivanje imunogenog pripravka, naznačen time da sadrži pripremu emulzije ulja u vodi postupkom prema bilo kojem od zahtjeva 1 do 13, pakiranje emulzije u prvi spremnik, te miješanja prvog spremnika u obliku kita sa drugim spremnikom, pri čemu drugi spremnik sadrži imunogen.
The rasagiline citrate of any one of claims 1-5, which has a water content, as determined by Karl Fischer analysis, of less than 5%. 
Rasagilin citrat prema jednom od patentnih zahtjeva 1-5, naznačen time, da ima sadržaj vode od manje od 5%, određen Karl Fischerovom analizom.
A composition comprising the rasagiline citrate of any one of claims 1-6 and a carrier, preferably the composition is a pharmaceutical composition and the carrier is a pharmaceutically acceptable carrier, more preferably the pharmaceutical composition is in the form of a tablet or a transdermal patch. The composition of claim 7, further comprising rasagiline base. 
Sastav naznačen time, da sadrži rasagilin citrat prema jednom od patentnih zahtjeva 1-6 i nosilac, sastav jest prvenstveno farmaceutski sastav, a nosilac je farmaceutski prihvatljivi nosilac, pogodnije je, da farmaceutski sastav jest u obliku tablete ili transdermalnog flastera.
The composition of claim 8, wherein the rasagiline base is present in an amount of less than 5% based on the total rasagiline content of the composition. 
Sastav prema patentnom zahtjevu 8, naznačen time, da je rasagilinska baza prisutna u količini manjoj od 5% u odnosu na ukupni sadržaj rasagilina u sastavu.
The composition of any one of claims 7-10, wherein the rasagiline content present in the form of rasagiline citrate is more than 50% of the total rasagiline content in the composition. 
Sastav prema jednom od patentnih zahtjeva 7-10, naznačen time, da sadržaj rasagilina u obliku rasagilin citrata iznosi više od 50% ukupnog sadržaja rasagilina u sastavu.
The composition of any one of claims 7-11, wherein the rasagiline citrate is mixed with a polymer. 
Sastav prema jednom od patentnih zahtjeva 7-11, naznačen time, da je rasagilin citrat pomiješan s polimerom.
The composition of any one of claims 7-12, further comprising stearic acid. 
Sastav prema jednom od patentnih zahtjeva 7-12, naznačen time, da nadalje sadrži stearinsku kiselinu.
A process for manufacture of the rasagiline citrate of any one of claims 1-6 or the composition of any one of claims 7-13, comprising: 
Postupak za proizvodnju rasagilin citrata prema jednom od patentnih zahtjeva 1-6, ili sastava prema jednom od patentnih zahtjeva 7-13, naznačen time, da obuhvaća:
combining a solution of citric acid with rasagiline base to form a first mixture; 
združivanje otopine limunske kiseline s rasagilinskom bazom da se oblikuje prva smjesa;
adding a solvent, preferably acetone, to the first mixture to form a second mixture; 
dodavanje otapala, prvenstveno acetona, prvoj smjesi da se oblikuje druga smjesa;
completely removing liquid, preferably at ambient temperature and at reduced pressure, from the second mixture; and 
potpuno odstranjivanje tekućine iz druge smjese, prvenstveno pri temperaturi okoline i pri sniženom pritisku; i
recovering the rasagiline citrate or preparing the composition. 
regeneriranje rasagilin citrata ili priprema sastava.
A stable pharmaceutical composition for the treatment of ocular hypertension of the kind that consists of the active molecules Timolol Maleate, Brimonidine Tartrate and Dorzolamide Hydrochloride, characterized by fundamentally consisting of the following excipients: Polyoxyl 40 Stearate, Sodium Borate crystals, Sodium Chloride and Benzalkonium chloride. 
Stabilna farmaceutska formulacija za liječenje okularne hipertenzije takva da sadrži aktivne molekule timolol maleat, brimonidin tartarat i dorzolamid hidroklorid, naznačena time što u biti sadrži sljedeće pomoćne tvari: polioksil 40 stearat, kristale natrijevog borata, natrijev klorid i benzalkonijev klorid.
A stable pharmaceutical composition for the treatment of ocular hypertension, as claimed in Claim 1, characterized by also consisting of the excipients: Hydroxypropyl-beta-cyclodextrines and Sodium Hyaluronate. 
Stabilna farmaceutska formulacija za liječenje okularne hipertenzije, prema zahtjevu 1, naznačena time što sadrži pomoćne tvari: hidroksipropil-beta-ciklodekstrine i natrijev hijaluronat.
A stable pharmaceutical composition for the treatment of ocular hypertension, as claimed in Claims 1, 2 and 3, characterized by consisting of the following quantitative composition: 
Stabilna farmaceutska formulacija za liječenje okularne hipertenzije, prema zahtjevima 1, 2 i 3, naznačena time što ima sljedeći kvantitativni sastav:
A stable pharmaceutical composition for the treatment of ocular hypertension, as claimed in Claim 2, characterized by consisting of a quantitative composition with the following content: 
[image] Stabilna farmaceutska formulacija za liječenje okularne hipertenzije, prema zahtjevu 2, naznačena time što ima kvantitativni sastav sa sljedećim sadržajem:
An injectable composition for the extended release of aripiprazole comprising a suspension of aripiprazole in an injection vehicle in an amount of at least 10 mg/ml comprising an optional viscosity enhancing agent, wherein the composition is free of sustained release matrices. 
Injektabilna smjesa za produljeno oslobađanje aripiprazola koja sadrži suspenziju aripiprazola u otopini za injekciju u količini od najmanje 10 mg/ml i po izboru sadrži sredstvo za povećanje viskoznosti, pri čemu u smjesi nema matrica za produljeno oslobađanje.
The composition of Claim 1, wherein the aripiprazole release is for at least 7 days. 
Smjesa prema zahtjevu 1, gdje je oslobađanje aripiprazola barem 7 dana.
The composition of Claims 1 or 2, wherein the viscosity enhancing agent comprises carboxymethyl cellulose. 
Smjesa prema zahtjevima 1 ili 2, gdje sredstvo za povećanje viskoznosti sadrži karboksimetil celulozu.
The composition of Claim 6, wherein the surfactant is selected from the group consisting of polysorbate 20, polysorbate 40, and polysorbate 80. 
Smjesa prema zahtjevu 6, pri čemu se površinski aktivno sredstvo bira iz skupine koja obuhvaća polisorbat 20, polisorbat 40 i polisorbat 80.
The injectable composition of claim 1 comprising at least 10 mg of aripiprazole, wherein said injection vehicle is an aqueous injection vehicle comprising water, a viscosity enhancing agent, a wetting agent and a tonicity adjusting agent. 
Injektabilna smjesa prema zahtjevu 1 koja sadrži najmanje 10 mg aripiprazola, pri čemu je otopina za injekciju vodena otopina za injekciju koja sadrži vodu, sredstvo za povećanje viskoznosti, sredstvo za vlaženje i sredstvo za podešavanje toničnosti.
The injectable composition of claim 1 comprising at least 10 mg of aripiprazole, wherein said injection vehicle is an aqueous injection vehicle comprising water, 3% by volume carboxymethylcellulose, 0.1% polysorbate 20 and 1% by weight sodium chloride. 
Injektabilna smjesa prema zahtjevu 1 koja sadrži najmanje 10 mg aripiprazola, pri čemu je otopina za injekciju vodena otopina za injekciju koja sadrži vodu, 3%vol karboksimetilceluloze, 0.1% polisorbata 20 i 1%tež natrijevog klorida.
The injectable composition of claim 1 comprising at least 10 mg of aripiprazole, wherein said injection vehicle is an aqueous injection vehicle consisting essentially of water, 3% by volume carboxymethylcellulose, 0.1% by weight polysorbate 20 and 0.9% by weight sodium chloride. 
Injektabilna smjesa prema zahtjevu 1 koja sadrži najmanje 10 mg aripiprazola, pri čemu je otopina za injekciju vodena otopina za injekciju koja u biti sadrži vodu, 3%vol karboksimetilceluloze, 0.1%tež polisorbata 20 i 0.9%tež natrijevog klorida.
The use of Claim 17, wherein the composition is administered intramuscularly or subcutaneously. 
Uporaba prema zahtjevu 17, gdje se smjesa primjenjuje u mišić ili potkožno.
The use of Claims 17 or 18 further comprising a second administration of the composition at least about 7 days after the first administration. 
Uporaba prema zahtjevu 17 ili 18 koja dalje obuhvaća drugu primjenu smjese najmanje 7 dana nakon prve primjene.
The use of Claims 17 or 18 further comprising a second administration of the composition at least about 14 days after the first administration. 
Uporaba prema zahtjevu 17 ili 18 koja dalje obuhvaća drugu primjenu smjese najmanje oko 14 dana nakon prve primjene.
The use of any of Claims 17 to 20, wherein the aripiprazole is present in an amount of at least 20 mg/ml. 
Uporaba prema bilo kojem od zahtjeva 17 do 20, pri čemu je aripiprazol prisutan u količini od najmanje 20 mg/ml.
The use of Claims 17 or 18, wherein a therapeutically effective amount of the aripiprazole is present in the plasma of the individual for at least 14 days. 
Uporaba prema zahtjevu 17 ili 18, gdje se terapijski učinkovita količina aripiprazola zadržava u plazmi pojedinca najmanje 14 dana.
The use of Claims 17 or 18, wherein a therapeutically effective amount of the aripiprazole is present in the plasma of the individual for at least 21 days. 
Uporaba prema zahtjevu 17 ili 18, gdje se terapijski učinkovita količina aripiprazola zadržava u plazmi pojedinca najmanje 21 dan.
is selected from the group consisting of hydrogen, C1-6alkyl, cycloalkyl, heterocyclyl, aryl(C1-6)alkyl, and heteroaryl(C1-6)alkyl; wherein when R1 is phenyl(C1-6)alkyl, phenyl is optionally fused to a heterocyclyl or cycloalkyl; 
Spoj formule (I) [image] naznačen time da: je izabran iz skupine koju čine vodik, C1-6alkil, cikloalkil, heterociklil, aril(C1-6)alkil, i heteroaril(C1-6)alkil;
wherein when R1 is C1-2alkyl, said C1-2alkyl is optionally substituted with one to two substituents independently selected from the group consisting of C1-6alkoxy, aryl, cycloalkyl, heterocyclyl, hydroxy, cyano, amino, C1-6alkylamino, (C1-6alkyl)2amino, trifluoromethyl, and carboxy; 
pri čemu kada R1 je C1-2alkil, navedeni C1-2alkil je proizvoljno supstituiran sa jednim do dva supstituenta nezavisno izabrana iz skupine koju čine C1-6alkoksi, aril, cikloalkil, heterociklil, hidroksi, cijano, amino, C1-6alkilamino, (C1-6alkil)2amino, trifluorometil, te karboksi;
and further, wherein when R1 is C3-6alkyl, said C3-6alkyl is optionally substituted with one to three substituents independently selected from the group consisting of C1-6alkoxy, aryl, cycloalkyl, heterocyclyl, hydroxy, cyano, amino, C1-6alkylamino, (C1-6alkyl)2amino, trifluoromethyl, and carboxy; 
te nadalje, pri čemu kada R1 je C3-6alkil, navedeni C3-6alkil je proizvoljno supstituiran s jednim do tri supstituenta nezavisno izabrana iz skupine koju čine C1-6alkoksi, aril, cikloalkil, heterociklil, hidroksi, cijano, amino, C1-6alkilamino, (C1-6alkil)2amino, trifluorometil, te karboksi;
is a substituent on a nitrogen atom of ring A selected from the group consisting of hydrogen and C1-4alkyl; 
je supstituent na atomu dušika prstena A izabran iz skupine koju čine vodik i C1-4alkil;
The compound of claim 1 wherein R1 is selected from the group consisting of hydrogen, C1-6alkyl, aryl(C1-4)alkyl, and heteroaryl(C1-4)alkyl; 
Spoj prema zahtjevu 1 naznačen time da R1 je izabran iz skupine koju čine vodik, C1-6alkil, aril(C1-4)alkil, i heteroaril(C1-4)alkil;
is selected from the group consisting of hydrogen, C1-6alkyl, cycloalkyl, heterocyclyl, aryl(C1-6)alkyl, and heteroaryl(C1-6)alkyl; wherein when R1 is phenyl(C1-6)alkyl, phenyl is optionally fused to a heterocyclyl or cycloalkyl; 
je izabran iz skupine koju čine vodik, C1-6alkil, cikloalkil, heterociklil, aril(C1-6)alkil, i heteroaril(C1-6)alkil; pri čemu kada R1 je fenil(C1-6)alkil, fenil je proizvoljno fuzioniran na heterociklil ili cikloalkil;
The compounds of claim 1 wherein R1 is selected from the group consisting of hydrogen, C1-6alkyl, aryl(C1-4)alkyl, and heteroaryl(C1-4)alkyl; 
Spoj prema zahtjevu 1 naznačen time da R1 je izabran iz skupine koju čine vodik, C1-6alkil, aril(C1-4)alkil, i heteroaril(C1-4)alkil;
A compound of Formula (Ia): wherein: 
Spoj formule (Ia): [image] naznačen time da:
Ra and Rb are independently hydrogen or C1-3alkyl; or, when Ra and Rb are each other than hydrogen, Ra and Rb are optionally taken together with the nitrogen atom to which they are both attached to form a five to seven membered monocyclic ring; and pharmaceutically acceptable enantiomers, diastereomers, racemates, and salts thereof, particularly wherein: 
Ra i Rb su nezavisno vodik ili C1-3alkil; ili, kada Ra i Rb svaki nisu vodik, Ra i Rb su proizvoljno uzeti zajedno sa dušikom na koji su oba spojeni da oblikuju pet do sedam člani monociklički prsten; i njihovi farmaceutski prihvatljivi enantiomeri, diastereomeri, racemati i soli.
a heterocycloalkyl group optionally substituted by one or more substituents selected from the group consisting of a halogen atom, a hydroxyl group, a C1-6 alkyl group, and -ORa22 (where Ra22 represents a C1-6 alkyl group]. 
heterocikloalkil skupinu proizvoljno supstituiranu sa jednim ili više supstituenata odabranih iz skupine koja sadrži atom halogena, hidroksil skupinu, C1-6 alkil skupinu, te -ORa22 (gdje Ra22 predstavlja C1-6 alkil skupinu].
The 1-thio-D-glucitol compound, or the pharmaceutically acceptable salt thereof, or the hydrate of the compound or the salt according to claim 1 or 2, wherein Ar1 is a heteroarylene group. 
Spoj 1-tio-D-glucitol, ili njegova farmaceutski prihvatljiva sol, ili hidrat spoja ili njegova sol prema zahtjevu 1 ili 2, naznačen time da Ar1 je heteroarilen skupina.
The drug according to claim 19, which is a drug for prophylaxis or treatment of diabetes, diabetes-related disease, or diabetic complication. 
Farmaceutski pripravak prema zahtjevu 22, naznačen time da je farmaceutski pripravak za profilaksu ili liječenje dijabetesa, bolesti povezanih sa dijabetesom, ili dijabetskih komplikacija.
A method for producing a 1-thio-D-glucitol compound of the following formula I, or a pharmaceutically acceptable salt thereof, or a hydrate of the compound or the salt: comprising the steps of: adding to a thiolactone of the following formula VIII more than 1 equivalent of a Grignard reagent of the following formula IX to obtain a compound V; 
Postupak dobivanja 1-tio-D-glucitol spoja prema slijedećoj formuli I, ili njegove farmaceutski prihvatljive soli, ili hidrata spoja ili njegove soli: [image] naznačen time da su Ar1, Ar2, A i R1-R10 kako je definirano u zahtjevu 1, te sadrži korake: dodavanja u tiolakton slijedeće formule VIII više od 1 ekvivalenta Grignardovog reagensa slijedeće formula IX da se dobije spoj V;
The method according to claim 26, wherein before the step of adding the Grignard reagent of the formula IX to the thiolactone of the formula VIII to obtain a compound V, about 0.8 to 1.2 equivalents of R30MgX (R30 represents a C1-8 alkyl group or a C3-7 cycloalkyl group, and X represents a halogen atom) is added to the thiolactone of the formula VIII. 
Postupak prema zahtjevu 26, naznačen time da se prije koraka dodavanja Grignardovog reagensa formule IX u tiolakton formule VIII da se dobije spoj V, oko 0.8 do 1.2 ekvivalenata R30MgX (R30 predstavlja C1-8 alkil skupinu ili C3-7 cikloalkil skupinu, te X predstavlja atom halogena) dodaje u tiolakton formule VIII.
adding to a compound of the following formula X a reagent of the following formula XI to obtain a compound XII; and 
dodavanje u spoj slijedeće formule X reagensa slijedeće formule XI da se dobije spoj XII; te
A compound of the following formula XIII, or a salt thereof, or a hydrate of the compound or the salt: [where Y represents a hydrogen atom or a hydroxyl group (provided that if Y is a hydrogen atom, the 1-position is of S-configuration), and R21, R22 R23 and R24 are the same or different, and each represent a hydrogen atom, a C1-6 alkyl group, -SiRa13, -CH2CH=CH2, -CO2Ra2, -CORb1, or a C7-l2 aralkyl group optionally substituted by one or more substituents selected from the group consisting of a halogen atom, -NO2 and -OMe (where Ra1 and Ra2 each represent a C1-6 alkyl group, and Rb1 represents a C1-6 alkyl group, a C7-10 aralkyl group, or a phenyl group), provided that if Y is a hydrogen atom, R21, R22, R23 and R24 are not hydrogen atoms at the same time; and the other symbols are as defined in claim 1]. 
Spoj prema slijedećoj formuli XIII, ili njegova sol, ili hidrat spoja ili njegova sol: [image] [gdje Y predstavlja atom vodika ili hidroksil skupinu (uz uvjet da ako Y je atom vodika, 1-položaj je u S-konfiguraciji), te, R22, R23 i R24 su isti ili različiti, te svaki predstavlja atom vodika, C1-6 alkil skupinu, -SiRa13, -CH2CH=CH2, -CO2Ra2, -CORb1 ili C7-12 aralkil skupinu proizvoljno supstituiranu sa jednim ili više supstituenata odabranih iz skupine koja sadrži atom halogena, -NO2 i -OMe (gdje Ra1 i Ra2 svaki predstavlja C1-6 alkil skupinu, te Rb1 predstavlja C1-6 alkil skupinu, C7-10 aralkil skupinu, ili fenil skupinu), uz uvjet da ako Y je atom vodika, R21, R22, R23 i R24 nisu istovremeno atomi vodika; i drugi simboli su kako je definirano u zahtjevu 1].
Use of a compound according to any one of claims 1 to 32 or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for the treatment of inflammatory diseases, disorders and conditions characterized by or associated with an undesirable inflammatory immune response, and all diseases and conditions induced by or associated with an excessive secretion of TNF-a and IL-1. 
Upotreba spoja, ili njegove farmaceutski prihvatljive soli ili solvata, u skladu s bilo kojim od patentnih zahtjeva 1 do 3 u proizvodnji medikamenta za liječenje upalnih bolesti, poremećaja i stanja, naznačena time što je ili je povezana s nepoželjnim upalnim imunosnim odgovorom, te svim bolestima i stanjima uzrokovanim ili povezanim s prekomjernim izlučivanjem TNF-a i IL-1.
Use of a compound according to any one of claims 1 to 32 or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for the treatment of inflammatory conditions and immune or anaphylactic disorders associated with infiltration of leukocytes into inflamed tissue. 
Upotreba spoja, ili njegove farmaceutski prihvatljive soli ili solvata, u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time što je navedeni spoj namijenjen proizvodnji medikamenta za liječenje upalnih stanja i imunosnih ili anafilaktičkih poremećaja povezanih s infiltracijom leukocita u upaljeno tkivo.
Use according to claim 11, wherein inflammatory conditions and immune disorders are selected from the group consisting of asthma, adult respiratory distress syndrome, chronic obstructive pulmonary disease, inflammatory bowel conditions, Crohn's disease, bronchitis, and cystic fibrosis. 
Upotreba u skladu s patentnim zahtjevom 11, naznačena time što se upalna stanja i imunosne poremećaje bira iz skupine koju čine astma, sindrom dišnog distresa kod odraslih, kronična opstruktivna plućna bolest, upalna stanja crijeva, Crohnova bolest, bronhitis i cistična fibroza.
Use according to claim 11, wherein said inflammatory conditions and immune disorders are selected from the group consisting of asthma, adult respiratory distress syndrome, bronchitis, cystic fibrosis, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis, uveitis, conjunctivitis, inflammatory bowel conditions, Crohn's disease, ulcerative colitis, distal proctitis, psoriasis, eczema, dermatitis, coronary infarct damage, chronic inflammation, endotoxin shock, and smooth muscle proliferation disorders. 
Upotreba u skladu s patentnim zahtjevom 11, naznačena time što se navedena upalna stanja i imunosne poremećaje bira iz skupine koju čine astma, sindrom dišnog distresa kod odraslih, bronhitis, cistična fibroza, reumatoidni artritis, reumatoidni spondilitis, osteoartritis, gihtični artritis, uveitis, konjunktivitis, upalna stanja crijeva, Crohnova bolest, ulcerozni kolitis, distalni proktitis, psorijaza, ekzem, dermatitis, oštećenje nakon koronarnog infarkta, kronična upala, endotoksinski šok, te poremećaji proliferacije glatkih mišića.
Use of a compound according to any one of claims 1 to 32 or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for the treatment of inflammatory diseases, disorders and conditions characterized by or associated by excessive unregulated production of cytokines or inflammatory mediators. 
Upotreba spoja, ili njegove farmaceutski prihvatljive soli ili solvata, u skladu s bilo kojim od patentnih zahtjeva 1 do 3 u proizvodnji medikamenta za liječenje upalnih bolesti, poremećaja i stanja, naznačena time što je ili je povezana s prekomjernom nereguliranom proizvodnjom citokina ili posrednika upale.
Use of a compound according to any one of claims 1 to 32 or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for the treatment of chronic obstructive pulmonary disease. 
Upotreba spoja, ili njegove farmaceutski prihvatljive soli ili solvata, u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time što je navedeni spoj namijenjen proizvodnji medikamenta za liječenje kronične opstruktivne plućne bolesti.
Use of a compound according to any one of claims 1 to 32 or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for the treatment of psoriasis. 
Upotreba spoja, ili njegove farmaceutski prihvatljive soli ili solvata, u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time što je navedeni spoj namijenjen proizvodnji medikamenta za liječenje psorijaze.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) mandipropamid. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) fluopiram.